{"id":"NCT02729909","sponsor":"Takeda","briefTitle":"Lubiprostone for Chronic Idiopathic Constipation Treatment","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-11","primaryCompletion":"2017-04-28","completion":"2017-06-05","firstPosted":"2016-04-06","resultsPosted":"2019-04-01","lastUpdate":"2019-04-01"},"enrollment":211,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Constipation"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":["AMITIZA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lubiprostone 24 μg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of oral administration of 24 ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.","primaryOutcome":{"measure":"Spontaneous Bowel Movement (SBM) Frequency at Week 1 of Administration","timeFrame":"Week 1","effectByArm":[{"arm":"Lubiprostone 24 μg","deltaMin":6.7,"sd":4.55},{"arm":"Placebo","deltaMin":5.2,"sd":2.82}],"pValues":[{"comp":"OG000 vs OG001","p":"0.020"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Mexico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Diarrhoea","Urinary tract infection","Headache","Influenza","Nausea"]}}